Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02996825
Title	Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	City of Hope Medical Center
Indications	triple-receptor negative breast cancer endometrial cancer ovarian cancer fallopian tube cancer peritoneum cancer
Therapies	Gemcitabine + Mirvetuximab Soravtansine
Age Groups:	senior \| adult \| child
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
City of Hope Medical Center		Duarte	California	91010	United States	Details
City of Hope Upland		Upland	California	91786	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field